metformin glp-1 combination weight loss glp 1 or Comparing Glucagon‐like peptide‐1 receptor agonists versus in drug‐naive patients: A nationwide cohort study - Sørensen - 2024 Diagram summarizing how metformin, gliclazide,

Drugs Context

This hormone promotes feelings of fullness and satiety, helping to reduce appetite and food intake

GLP-1 and glucose-dependent insulinotropic polypeptide

About the UTSW Weight Wellness Program We are the only academic medical center in North Texas with a dedicated, multidisciplinary weight management team of obesity medicine physicians, advanced practice providers, dietitians, and mental health professionals

Potential implications of the new pharmacotherapies on obesity management The mean WL in clinical trials with the most efficacious new obesity pharmacotherapies ranges between 15% and 25% at 1 year (and it may be even higher for some agents that have not reached weight plateau at study completion)

Interestingly, GLP-1 is also produced in a smaller amount in the brainstem, specifically the nucleus of the solitary tract